|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2007. AZD-103/ELND-005
In 2006, we entered into a collaboration with Transition to
develop a small molecule approach to the treatment of mild to
moderate Alzheimer’s disease. The molecule is a
beta-amyloid
anti-aggregate. Based upon pre-clinical data, by blocking the
aggregation of amyloid beta, clearance of amyloid occurs and
plaque build up is prevented.
Daily oral treatment with this compound has been shown to
prevent cognition decline in a transgenic mouse model of
Alzheimer’s disease, with reduced amyloid plaque load in
the brain accompanied with an increased survival rate of these
animals.
In 2006, three Phase 1 Single Ascending Dose studies were
conducted by Transition showing that AZD-103/ELND-005 has a
favorable pharmacokinetic profile and is safe and well
tolerated. No significant drug-related adverse events have been
reported to date.
In 2007, we will conduct additional clinical and non-clinical
studies to support the initiation of a Phase 2 trial,
targeted for 2007. This Phase 2 study will be a randomized,
double-blind, placebo-controlled, dose-ranging study in mild to
moderate Alzheimer’s disease patients.
Table of Contents
|
| |||||||
